Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2009
Safinamide as an adjunct to levodopa significantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study
R. Borgohain, J. Szasz, M. Bhatt, S. Rossetti, V. Lucini, R. Anand, on behalf of the Study 016 investigators, Hyderabad, India, Targu Mures, Romania, Mumbai, India, Bresso, Italy, St Moritz, Switzerland
XVIII WFN World Congress on Parkinson's Disease and Related Disorders Miami Beach, Fl, USA December 13-16 2009
Improvements in symptom severity and daily living with safinamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study
J. Szasz, R. Borgohain, M. Bhatt, S. Rossetti, V. Lucini, R. Anand, on behalf of the Study 016 investigators, Targu Mures, Romania, Hyderabad, Mumbai, India, Bresso, Italy, St Moritz, Switzerland
XVIII WFN World Congress on Parkinson's Disease and Related Disorders,Miami Beach, Fl, USA December 13-16 2009
NW-3509: a novel potent sodium channel blocker with antipsychotic potential
E.Izzo,L. Faravelli, E. Colombo, A.Ieraci, M.Calabresi, S.Meli, S.Parini, C.Sabido-David, K.Wedzony, M. Bortolato, R. Frau, V. Bini, C. Caccia,P. Melloni, P. Salvati
39th Annual meeting of the Society for Neuroscience October 17-21, 2009 - Chicago
Hyperactivity induced by amphetamine/chlordiazepoxide mixture in mice as a pharmacological model to identify novel compounds with potential for bipolar disorders.
A. Ieraci, S. Meli, P. Salvati, E. Izzo
Sins October 2-5, 2009
NW-3509: a novel potent sodium channel blocker with antipsychotic potential
E. Izzo, L. Faravelli, E. Colombo, A. Ieraci, M Calabresi, S. Meli, S. Parini, C. Sabido-David, K Wedzony, M. Bortolato, R. Frau, V. Bini, C. Caccia, P. Melloni, P. Salvati
22nd ECNP Congress, 12 - 16 September 2009, Istanbul, Turkey (Istanbul Convention & Exhibition Centre)
Oral ralfinamide suppresses autotomy following hindpaw deafferentation by multiple dorsal rhizotomies, a rat model of CNS-mediated spontaneous neuropathic pain
Shou WT, Sun HL, Yu J, Zhao DD, Faravelli L, Chen Z, Zhang SH, Seltzer Z'.
6th International Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9-12, 2009
Efficacy and safety of safinamide in patients with Parkinson's disease experiencing motor fluctuations:results of a 6 month Phase III, randomised,double-blind, placebo controlled study.
Rupam Borgohain, Jozsef Szasz, Mohit Bhatt, Stefano Rossetti, Valentina Lucini, Ravi Anand.
MDS conference - June 7-11, 2009 - Paris, France